When severe infections reach a desperate situation where there are no drugs available for treatment, “superbugs”—multidrug-resistant bacteria—become invisible killers that devour health. They gradually break through the defenses of traditional antibiotics, leaving antimicrobial therapy in a dilemma of having run out of options. The emergence of “Rilabactam” is like a ray of dawn piercing through the haze, bringing new hope and possibilities...

Currently, infections caused by multi-drug resistant organisms (MDR) such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) have become significant challenges in clinical treatment. According to the WHO, such infections are responsible for approximately 1.27 million deaths each year. Fosfomycin sodium, due to its unique mechanism of action, plays a crucial role in combination therapies...

Having been deeply involved in the pharmaceutical industry for 20 years, Jingjing Pharmaceutical has always adhered to the philosophy of "harmony and excellence, combining to form a crystal." It regards research and development innovation as the core driving force for corporate growth, establishing a research and development system that covers multiple fields and combines professionalism with innovation. With its technical expertise, the company lays a solid foundation for cooperation with its clients, injecting strong momentum into the cause of health.

When health becomes an essential need of the times, and innovation becomes a consensus in the industry, Jingjing Pharmaceutical has been diligently working for 20 years, adhering to its original vision with craftsmanship and embarking on new journeys through innovation. Based in the biomanufacturing industry, Jingjing Pharmaceutical operates with the core philosophy of “harmony among all, refinement through unity,” and has built a tripartite core competitiveness that integrates research and development, products, and services.

In the wave of the global pharmaceutical industry's transformation towards "innovation, sustainability, and integration," CDMOs (Contract Development and Manufacturing Organizations) and CMOs (Contract Manufacturing Organizations), as core hubs of the pharmaceutical supply chain, play a vital role in connecting drug research and development with commercial production, thus becoming a significant force in driving the efficient development of the pharmaceutical industry. Domestic characteristics and original...

Fosfomycin sodium, as a broad-spectrum antibiotic, operates by inhibiting the early synthesis of the bacterial cell wall. This mechanism differs from the targets of other mainstream antimicrobial drugs such as β-lactams, aminoglycosides, and quinolones. This uniqueness endows it with significant advantages in terms of its antibacterial spectrum, resistance profile, and safety profile. The following information relates to its comparison with similar drugs in the same class/clinical setting...

What is AKG? The “core component” of the cellular energy factory AKG (Alpha-Ketoglutarate) is a key intermediate metabolite in the tricarboxylic acid cycle (TCA cycle, also known as the Krebs cycle). Simply put, it is an essential “hub molecule” in the process by which cells convert food into energy. If…

Rulibactam, a product of Jingjing Pharmaceutical, has the following advantages compared to traditional β-lactamase inhibitors: it has a stable structure, does not induce drug resistance, and has a broad spectrum of enzyme inhibition. Rulibactam is a novel β-lactamase inhibitor with a DBO (Dibenzoyl-Oxazoline) structure. Its key characteristic is the absence of a β-lactam ring structure, which means it must be used in combination with imipenem or cilastatin to exert its antibacterial effect. This drug is primarily used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.

精晶药业-危险废物管理制度 附件精晶药业-危险废物管理制度.pdf

精晶药业-危废培训管理办法 附件精晶药业-危废培训管理办法.pdf